Bajaj Healthcare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.6%+14.6%−29.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+27.2%+8.1%−28.6%
+41.8%+12.0%−38.8%
−60.1%+147.1%−294.8%
−62.5%+143.8%−294.7%
+10.8%+8.9%−15.1%
+14.3%+67.5%−24.3%
+168.6%−76.6%+513.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BAJAJHCARE₹312.85

Bajaj Healthcare Limited

· Pharma & Health
₹ CrorePeersTHEMISMEDLINCOLNWANBURYSIGACHIAHCLANUHPHRAMRUTANJANMcap ₹1,053 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-29.7+14.6+12.6—
EBITDA Growth—-28.6+8.1+27.2—
EBIT Growth—-38.8+12.0+41.8—
Net Income Growth—-294.8+147.1-60.1—
EPS Growth—-294.7+143.8-62.5—
Total Assets Growth—-15.1+8.9+10.8—
Total Equity Growth—-24.3+67.5+14.3—
Cash from Operations Growth—+513.4-76.6+168.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.